Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-1: Orforglipron in Adults With Obesity or Overweight and Comorbidities
jRCT2031230136Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of orforglipron in obesity and Overweight (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Mean percent change from baseline in body weight. Started Jul 2023; status: active, not recruiting.
02
Drugs
orforglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on jRCT2031230136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230136.